아티초크 추출물
Artichoke Extract
📚 관련 논문 (21편)
1. Phytother Res. 2019 Jan;33(1):55-71. doi: 10.1002/ptr.6213. Epub 2018 Oct 22. The antioxidant activity of artichoke (Cynara scolymus): A systematic review and meta-analysis of animal studies. Salekzamani S(1), Ebrahimi-Mameghani M(1), Rezazadeh K(1). Author information: (1)Nutrition Research
2. Crit Rev Food Sci Nutr. 2018;58(15):2549-2556. doi: 10.1080/10408398.2017.1332572. Epub 2017 Aug 24. Lipid-lowering activity of artichoke extracts: A systematic review and meta-analysis. Sahebkar A(1), Pirro M(2), Banach M(3)(4), Mikhailidis DP(5), Atkin SL(6), Cicero AFG(7). Author informa
3. Nutrients. 2022 May 18;14(10):2099. doi: 10.3390/nu14102099. Effect of Dietary Supplementation with Eufortyn(®) Colesterolo Plus on Serum Lipids, Endothelial Reactivity, Indexes of Non-Alcoholic Fatty Liver Disease and Systemic Inflammation in Healthy Subjects with Polygenic Hypercholesterolem
4. Nutr J. 2022 Sep 26;21(1):59. doi: 10.1186/s12937-022-00813-w. Effect of TCF7L2 on the relationship between lifestyle factors and glycemic parameters: a systematic review. Hosseinpour-Niazi S(1), Mirmiran P(2), Hosseini S(3), Hadaegh F(4), Ainy E(5), Daneshpour MS(6), Azizi F(7). Author info
5. Cochrane Database Syst Rev. 2013 Mar 28;(3):CD003335. doi: 10.1002/14651858.CD003335.pub3. Artichoke leaf extract for treating hypercholesterolaemia. Wider B(1), Pittler MH, Thompson-Coon J, Ernst E. Author information: (1)Institute of Health Services Research, University of Exeter Medical Sc
6. Cochrane Database Syst Rev. 2009 Oct 7;(4):CD003335. doi: 10.1002/14651858.CD003335.pub2. Artichoke leaf extract for treating hypercholesterolaemia. Wider B(1), Pittler MH, Thompson-Coon J, Ernst E. Author information: (1)Complementary Medicine, Peninsula Medical School, Universities of Exete
7. Cochrane Database Syst Rev. 2002;(3):CD003335. doi: 10.1002/14651858.CD003335. Artichoke leaf extract for treating hypercholesterolaemia. Pittler MH(1), Thompson CO, Ernst E. Author information: (1)Department of Complementary Medicine, University of Exeter, 25 Victoria Park Road, Exeter, Devo
1. Atherosclerosis. 2025 Apr;403:119177. doi: 10.1016/j.atherosclerosis.2025.119177. Epub 2025 Mar 22. The effects of a novel nutraceutical combination on low-density lipoprotein cholesterol and other markers of cardiometabolic health in adults with hypercholesterolaemia: A randomised double-blind placebo-controlled trial. Stonehouse W(1), Benassi-Evans B(2), Louise J(3). Author information: (1)Commonwealth Scientific Industrial Research Organisation (CSIRO), Health and Biosecurity, Adelaide, South Australia, Australia. Electronic address: welma.stonehouse@deakin.edu.au. (2)Commonwealth Scientific Industrial Research Organisation (CSIRO), Health and Biosecurity, Adelaide, South Australia, Australia. Electronic address: bianca.benassi@csiro.au. (3)Biostatistics Unit, South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia. BACKGROUND AND AIM: Clinical evidence exists for LDL-cholesterol lowering by plant sterols, bergamot extract and artichoke leaf extract individually but their effect when combined is unknown. This study investigated the effects of a novel nutraceutical combining plant sterols, bergamot extract, artichoke leaf extract and hydroxytyrosol (referred to as 'Cholesterol Balance'), on serum LDL-cholesterol (primary outcome), other cardiometabolic and oxidative stress markers in adults with hypercholesterolaemia. METHODS: Healthy adults (n = 42, 18-<66 years, body mass index [BMI] >18.5-<35 kg/m2), with mild hypercholesterolaemia (LDL-cholesterol ≥2.5-<5 mmol/L) and low CVD risk participated in a 4-month double-blind randomised placebo-controlled trial. Participants consumed either 3 capsules/day Cholesterol Balance (providing 375 mg Bergavit40™, 150 mg Altilix™, 1.8 g phytosterols, and 50 mg of Hydrovas10™ daily) or placebo. Outcomes were assessed at baseline, 2- and 4-months. RESULTS: There was no evidence that Cholesterol Balance affected serum LDL-cholesterol compared to placebo (adjusted mean difference [95 % CI] at 4 months between treatments, -0.12 [-0.34, 0.11] mmol/L, p = 0.307). None of the secondary outcomes, including total cholesterol, HDL-cholesterol, triglycerides, non-HDL-cholesterol, total cholesterol:HDL-cholesterol ratio, apolipoprotein A1 (ApoA1), apolipoprotein B (ApoB), ApoB:ApoA1 ratio, plasma oxidised LDL, serum malondialdehyde, HbA1c, blood pressure or safety markers showed a significant difference between groups. CONCLUSION: While safe to consume, a nutraceutical containing plant sterols, bergamot extract, artichoke leaf extract and hydroxytyrosol did not show evidence of improving serum LDL-cholesterol, or any other lipid and oxidative stress markers in adults with mild hypercholesterolaemia. Further research is needed to determine if ingredients in the complex formulation interact or interfere with LDL-cholesterol lowering mechanisms. Copyright © 2025 The Authors. Published by Elsevier B.V. All rights reserved. DOI: 10.1016/j.atherosclerosis.2025.119177 PMID: 40147213 [Indexed for MEDLINE] Conflict of interest statement: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
2. Int J Obes (Lond). 2024 Dec;48(12):1696-1704. doi: 10.1038/s41366-024-01590-8. Epub 2024 Jul 20. Enhancing gut microbiota and microbial function with inulin supplementation in children with obesity. Visuthranukul C(1), Sriswasdi S(2)(3), Tepaamorndech S(4), Chamni S(5), Leelahavanichkul A(4)(6), Joyjinda Y(7)(8), Aksornkitti V(3)(9), Chomtho S(10). Author information: (1)Center of Excellence in Pediatric Nutrition, Division of Nutrition, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand. chonnikant.v@chula.ac.th. (2)Research Affairs, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand. (3)Center of Excellence in Computational Molecular Biology, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand. (4)Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand. (5)Center of Excellent in Natural Products and Nanoparticles (NP2), Department of Pharmacognosy and Pharmaceutical Botany, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, 10330, Thailand. (6)Center of Excellence in Inflammation and Immunology Research Unit (CETRII), Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand. (7)WHO-CC for Research and Training on Viral Zoonoses, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand. (8)Thai Red Cross Emerging Infection Diseases-Health Science Center, Bangkok, 10330, Thailand. (9)Department of Anatomy, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand. (10)Center of Excellence in Pediatric Nutrition, Division of Nutrition, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand. BACKGROUND AND OBJECTIVES: Gut dysbiosis that resulted from the alteration between host-microbe interaction might worsen obesity-induced systemic inflammation. Gut microbiota manipulation by supplementation of prebiotic inulin may reverse metabolic abnormalities and improve obesity. This study aimed to determine whether inulin supplementation improved intestinal microbiota and microbial functional pathways in children with obesity. METHODS: Children with obesity whose BMI above median + 2SDs were recruited to a randomized, double-blinded placebo-controlled study. The participants aged 7-15 years were assigned to inulin supplement extracted from Thai Jerusalem artichoke (intervention), maltodextrin (placebo), and dietary fiber advice groups. All participants received similar monthly conventional advice and follow-up for 6 months. Fecal samples were collected for gut microbiome analysis using 16S rRNA sequencing. Phylogenetic Investigation of Communities by Reconstruction of Unobserved States was performed to infer microbial functional pathways. RESULTS: One hundred and forty-three children with available taxonomic and functional pathway abundance profiles were evaluated. A significant increase in alpha-diversity was observed in the inulin group. Inulin supplementation substantially enhanced Bifidobacterium, Blautia, Megasphaera, and several butyrate-producing bacteria, including Agathobacter, Eubacterium coprostanoligenes, and Subdoligranulum, compared to the other groups. The inulin group showed a significant difference in functional pathways of proteasome and riboflavin metabolism. These changes correlated with clinical and metabolic outcomes exclusively in the inulin group. CONCLUSIONS: Inulin supplementation significantly promoted gut bacterial diversity and improved gut microbiota dysbiosis in children with obesity. The modulation of functional pathways by inulin suggests its potential to establish beneficial interactions between the gut microbiota and host physiology. Inulin supplementation could be a strategic treatment to restore the balance of intestinal microbiota and regulate their functions in childhood obesity. © 2024. The Author(s). DOI: 10.1038/s41366-024-01590-8 PMCID: PMC11584386 PMID: 39033197 [Indexed for MEDLINE] Conflict of interest statement: Competing interests: The authors declare no competing interests. Ethics approval and consent to participate: The research involving human subjects, human material, and human data was in accordance with the Declaration of Helsinki. The study was approved by the Institutional Review Board, Faculty of Medicine, Chulalongkorn University (IRB no. 240/60). Informed assent and consent were obtained from all participants and their parents prior to enrollment.
3. Nutrients. 2024 May 23;16(11):1587. doi: 10.3390/nu16111587. A Randomized, Double-Blind, Placebo-Controlled Clinical Trial on the Effect of a Dietary Supplement Containing Dry Artichoke and Bergamot Extracts on Metabolic and Vascular Risk Factors in Individuals with Suboptimal Cholesterol Levels. Fogacci F(1)(2), Giovannini M(1), Di Micoli A(3), Fiorini G(3), Grandi E(1)(3), Borghi C(1)(3), Cicero AFG(1)(3). Author information: (1)Hypertension and Cardiovascular Risk Research Group, Medical and Surgical Sciences Department, Sant'Orsola-Malpighi University Hospital, 40138 Bologna, Italy. (2)Italian Nutraceutical Society (SINut), 40138 Bologna, Italy. (3)Cardiovascular Medicine Uniti, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy. The aim of this study was to assess whether dietary supplementation with a nutraceutical blend comprising extracts of bergamot and artichoke-both standardized in their characteristic polyphenolic fractions-could positively affect serum lipid concentration and insulin sensitivity, high-sensitivity C-reactive protein (hs-CRP), and indexes of non-alcoholic fatty liver disease (NAFLD) in 90 healthy individuals with suboptimal cholesterol levels. Participants were randomly allocated to treatment with a pill of either active treatment or placebo. After 6 weeks, the active-treated group experienced significant improvements in levels of triglycerides (TG), apolipoprotein B-100 (Apo B-100), and apolipoprotein AI (Apo AI) versus baseline. Total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), non-high density lipoprotein cholesterol (Non-HDL-C), and hs-CRP also significantly decreased in the active-treated group compared to both baseline and placebo. At the 12-week follow-up, individuals allocated to the combined nutraceutical experienced a significant improvement in TC, LDL-C, Non-HDL-C, TG, Apo B-100, Apo AI, glucose, alanine transaminase (ALT), gamma-glutamyl transferase (gGT), hs-CRP, several indexes of NAFLD, and brachial pulse volume (PV) in comparison with baseline. Improvements in TC, LDL-C, Non-HDL-C, TG, fatty liver index (FLI), hs-CRP, and endothelial reactivity were also detected compared to placebo (p < 0.05 for all). Overall, these findings support the use of the tested dietary supplement containing dry extracts of bergamot and artichoke as a safe and effective approach for the prevention and management of a broad spectrum of cardiometabolic disorders. DOI: 10.3390/nu16111587 PMCID: PMC11174436 PMID: 38892519 [Indexed for MEDLINE] Conflict of interest statement: The authors declare no conflict of interest. Meda Pharma S.p.A. (Monza, MB, Italy) had no role in data collection, analysis, and interpretation. Meda Pharma S.p.A. (Monza, MB, Italy) did not even interfere in the writing of the manuscript and the decision to publish it.
4. Arch Med Sci. 2023 Jun 17;19(5):1169-1179. doi: 10.5114/aoms/167969. eCollection 2023. Three arms, double-blind, non-inferiority, randomized clinical study testing the lipid-lowering effect of a novel dietary supplement containing red yeast rice and artichoke extracts compared to Armolipid Plus(®) and placebo. Cicero AFG(1)(2), Fogacci F(1)(2), Tocci G(3), D'Addato S(2), Grandi E(2), Banach M(4)(5)(6)(7), Borghi C(1)(2)(3)(4). Author information: (1)Hypertension and Cardiovascular Risk Research Group, Medical and Surgical Sciences Department, University of Bologna, Bologna, Italy. (2)Italian Nutraceutical Society (SINut), Bologna, Italy. (3)Division of Cardiology, Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, University of Rome Sapienza, Sant'Andrea Hospital, Rome, Italy. (4)Department of Preventive Cardiology and Lipidology, Medical University of Lodz (MUL), Lodz, Poland. (5)Department of Cardiology and Congenital Diseases of Adults, Polish Mother's Memorial Hospital Research Institute (PMMHRI), Lodz, Poland. (6)Cardiovascular Research Centre, University of Zielona Gora, Zielona Gora, Poland. (7)Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, MD, United States. INTRODUCTION: There is growing interest in head-to-head comparison between different lipid-lowering nutraceuticals. The aim of our study was to test the lipid-lowering effect of dietary supplementation with low-dose monacolins from red yeast rice (2.8 mg per daily dose) combined with berberine (Armolipid Plus®) or highly standardized artichoke extract versus placebo. MATERIAL AND METHODS: 60 overall healthy adult volunteers with polygenic hypercholesterolemia (baseline low-density lipoprotein cholesterol (LDL-C) = 160.2 ±9.2 mg/dl) were enrolled in a 3-arm, double-blind, non-inferiority, randomized, parallel-group clinical trial. After 4-week diet standardization, enrolled individuals were randomized to be treated for 8 weeks with red yeast rice and highly standardized artichoke extracts (ATC group), Armolipid Plus®, or placebo. RESULTS: At the enrolment visit, LDL-C values were similar in the compared groups. After 8 weeks, all actively treated subjects experienced significant improvements in baseline total cholesterol (TC), LDL-C and apolipoprotein B (Apo-B) (all p < 0.01) (ATC group: TC = -18.9%, LDL-C = -26.7% (placebo-corrected: -12.4%), Apo-B = -19.6%; Armolipid Plus®: TC = -18.4%, LDL-C = -25.8% (placebo-corrected: -12.1%), Apo-B = -23.2%; placebo: TC = -6.2%, LDL-C = -8%, Apo-B = -8.4%). Participants in the ATC group attained significantly lower body mass index (BMI) values (-2.1%), while individuals treated with Armolipid Plus® showed improvements in baseline high-density lipoprotein cholesterol (HDL-C) (+8.7%) and triglyceride (TG) (+17.5%) levels. Finally, baseline hepatic steatosis index (HSI) values significantly decreased in both actively treated groups (by -2.4% and -2.4% in ATC and in Armolipid Plus®, respectively). CONCLUSIONS: Patients with polygenic hypercholesterolemia experienced a significant improvement in several cardiovascular risk factors in both ATC and Armolipid Plus® groups. Copyright: © 2023 Termedia & Banach. DOI: 10.5114/aoms/167969 PMCID: PMC10507752 PMID: 37732047 Conflict of interest statement: The authors declare no conflict of interest.
5. J Transl Med. 2022 Aug 19;20(1):377. doi: 10.1186/s12967-022-03579-1. A new nutraceutical (Livogen Plus®) improves liver steatosis in adults with non-alcoholic fatty liver disease. Ferro Y(#)(1), Pujia R(#)(1), Mazza E(1), Lascala L(2), Lodari O(2), Maurotti S(2), Pujia A(1)(3), Montalcini T(4)(5). Author information: (1)Department of Medical and Surgical Science, University Magna Græcia, 88100, Catanzaro, Italy. (2)Department of Clinical and Experimental Medicine, University Magna Greæcia, Catanzaro, Italy. (3)Research Center for the Prevention and Treatment of Metabolic Diseases (CR METDIS), University Magna Græcia, 88100, Catanzaro, Italy. (4)Department of Clinical and Experimental Medicine, University Magna Greæcia, Catanzaro, Italy. tmontalcini@unicz.it. (5)Research Center for the Prevention and Treatment of Metabolic Diseases (CR METDIS), University Magna Græcia, 88100, Catanzaro, Italy. tmontalcini@unicz.it. (#)Contributed equally BACKGROUND: Currently, there is no approved medication for non-alcoholic fatty liver disease management. Pre-clinical and clinical studies showed that several bioactive molecules in plants or foods (i.e., curcumin complex, bergamot polyphenol fraction, artichoke leaf extract, black seed oil, concentrate fish oil, picroliv root, glutathione, S-adenosyl-L-methionine and other natural ingredients) have been associated with improved fatty liver disease. Starting from these evidences, our purpose was to evaluate the effects of a novel combination of abovementioned nutraceuticals as a treatment for adults with fatty liver disease. METHODS: A total of 140 participants with liver steatosis were enrolled in a randomized, double-blind, placebo controlled clinical trial. The intervention group received six softgel capsules daily of a nutraceutical (namely Livogen Plus®) containing a combination of natural bioactive components for 12 weeks. The control group received six softgel capsules daily of a placebo containing maltodextrin for 12 weeks. The primary outcome measure was the change in liver fat content (CAP score). CAP score, by transient elastography, serum glucose, lipids, transaminases, and cytokines were measured at baseline and after intervention. RESULTS: After adjustment for confounding variables (i.e., CAP score and triglyceride at baseline, and changes of serum γGT, and vegetable and animal proteins, cholesterol intake at the follow-up), we found a greater CAP score reduction in the nutraceutical group rather than placebo (- 34 ± 5 dB/m vs. - 20 ± 5 dB/m, respectively; p = 0.045). The CAP score reduction (%) was even greater in those with aged 60 or less, low baseline HDL-C, AST reduction as well as in men. CONCLUSION: Our results showed that a new combination of bioactive molecules as nutraceutical was safe and effective in reducing liver fat content over 12 weeks in individuals with hepatic steatosis. Trial registration ISRCTN, ISRCTN70887063. Registered 03 August 2021-retrospectively registered, https://doi.org/10.1186/ISRCTN70887063. © 2022. The Author(s). DOI: 10.1186/s12967-022-03579-1 PMCID: PMC9392294 PMID: 35986358 [Indexed for MEDLINE] Conflict of interest statement: The authors declare that they have no competing interests.
6. Sci Rep. 2022 Jul 29;12(1):13014. doi: 10.1038/s41598-022-17220-0. Effects of inulin supplementation on body composition and metabolic outcomes in children with obesity. Visuthranukul C(1), Chamni S(2), Kwanbunbumpen T(3), Saengpanit P(3), Chongpison Y(4)(5), Tepaamorndech S(6)(7), Panichsillaphakit E(3), Uaariyapanichkul J(1)(3), Nonpat N(2), Chomtho S(8). Author information: (1)Pediatric Nutrition Research Unit, Division of Nutrition, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, 1873 Rama 4 Road, Pathumwan, Bangkok, 10330, Thailand. (2)Natural Products and Nanoparticles Research Unit, Department of Pharmacognosy and Pharmaceutical Botany, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, 10330, Thailand. (3)Division of Nutrition, Department of Pediatrics, King Chulalongkorn Memorial Hospital, The Thai Red Cross Society, Bangkok, 10330, Thailand. (4)The Skin and Allergy Research Unit, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand. (5)Biostatistics Excellence Center, Research Affairs, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand. (6)National Center for Genetic Engineering and Biotechnology (BIOTEC), Pathumthani, 10210, Thailand. (7)Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand. (8)Pediatric Nutrition Research Unit, Division of Nutrition, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, 1873 Rama 4 Road, Pathumwan, Bangkok, 10330, Thailand. sirinuch.c@chula.ac.th. Inulin might improve body composition in obese children. We aimed to determine the effects of inulin supplementation on body composition and metabolic outcomes in obese children. A randomized, double-blinded placebo-controlled study was conducted in obese Thai children aged 7-15 years. Participants were assigned to 3 treatment groups for 6 months: 13 g of extracted inulin powder from Thai Jerusalem artichoke, isocaloric maltodextrin, and dietary fiber advice groups. Body composition was assessed by bioelectrical impedance analysis. One-hundred and fifty-five children completed the study (mean age 10.4 ± 2.2 years, BMI z-score 3.2 ± 1.0, 59% male). The drop-out rate was 6%. The inulin extract yielded more than 90% compliance without significant gastrointestinal side effects. All three groups demonstrated a significant decrease in BMI z-score, fat mass index (FMI), and trunk FMI, but the differences between groups were not observed. Fat-free mass index significantly increased only in the inulin group (16.18 ± 1.90 vs. 16.38 ± 1.98 kg/m2, P = 0.009). There were no significant differences in the metabolic profiles between groups. Despite showing no substantial effect on adiposity, inulin may increase fat-free mass in obese children. Further research in the change of gut microbiota composition is needed to determine inulin's impact on host-microbe interaction in pediatric obesity. © 2022. The Author(s). DOI: 10.1038/s41598-022-17220-0 PMCID: PMC9338247 PMID: 35906473 [Indexed for MEDLINE] Conflict of interest statement: The authors declare no competing interests.
7. Nutrients. 2021 Dec 27;14(1):108. doi: 10.3390/nu14010108. Artichoke and Bergamot Phytosome Alliance: A Randomized Double Blind Clinical Trial in Mild Hypercholesterolemia. Riva A(1), Petrangolini G(1), Allegrini P(1), Perna S(2), Giacosa A(3), Peroni G(4), Faliva MA(4), Naso M(4), Rondanelli M(5)(6). Author information: (1)Development Department, Indena SpA, 20139 Milan, Italy. (2)Department of Biology, College of Science, Sakhir Campus, University of Bahrain, Zallaq 32038, Bahrain. (3)CDI-Centro Diagnostico Italiano, 20147 Milan, Italy. (4)Endocrinology and Nutrition Unit, Azienda di Servizi alla Persona ''Istituto Santa Margherita'', University of Pavia, 27100 Pavia, Italy. (5)IRCCS Mondino Foundation, 27100 Pavia, Italy. (6)Unit of Human and Clinical Nutrition, Department of Public Health, Experimental and Forensic Medicine, University of Pavia, 27100 Pavia, Italy. Botanicals are natural alternatives to pharmacological therapies that aim at reducing hypercholesterolemia. In this context, despite bergamot being effective in modulating lipid profile, some subjects failed to achieve a satisfactory response to supplementation. The aim of this study was to evaluate whether the association of 600 mg of bergamot phytosome® (from Citrus Bergamia Risso) and 100 mg of artichoke leaf standardized dry extract (from Cynara cardunculus L.) can be an alternative in patients with mild hypercholesterolemia who are poor responders to bergamot in a 2-month randomized placebo-controlled trial. Sixty overweight adults were randomized into two groups: 30 were supplemented and 30 received a placebo. The metabolic parameters and DXA body composition were evaluated at the start, after 30 and 60 days. Between the two groups, total and LDL cholesterol in the supplemented group (compared to placebo) showed significant decreases overtime. A significant reduction of waist circumference and visceral adipose tissue (VAT) was recorded in the supplemented group (compared to placebo), even in subjects who did not follow a low-calorie diet. In conclusion, the synergism between Citrus Bergamia polyphenols and Cynara cardunculus extracts may be an effective option and may potentially broaden the therapeutic role of botanicals in dyslipidemic patients. DOI: 10.3390/nu14010108 PMCID: PMC8746931 PMID: 35010984 [Indexed for MEDLINE] Conflict of interest statement: A.R., G.P. (Giovanna Petrangolini) and P.A. are employees of Indena. S.P., A.G., G.P. (Gabriella Peroni), M.F., M.N. and M.R. declare no conflict of interest.
8. Phytother Res. 2021 Dec;35(12):6607-6623. doi: 10.1002/ptr.7247. Epub 2021 Sep 27. Effects of artichoke leaf extract supplementation or artichoke juice consumption on lipid profile: A systematic review and dose-response meta-analysis of randomized controlled trials. Shahinfar H(1)(2), Bazshahi E(3), Amini MR(4), Payandeh N(3), Pourreza S(3), Noruzi Z(3), Shab-Bidar S(3). Author information: (1)Department of Nutrition, School of Public Health, Iran University of Medical Sciences, Tehran, Iran. (2)Student Research Committee, Faculty of Public Health, Iran University of Medical Sciences, Tehran, Iran. (3)Department of Community Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences (TUMS), Tehran, Iran. (4)Department of Community Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran. Accumulating evidence regarding the effect of artichoke on lipid profile is equivocal. We updated a previous meta-analysis on the effect of artichoke extract supplementation on lipid profile and performed dose-response analysis. We searched PubMed, Scopus, Web of Science, and Cochrane Library from inception to June 2021 using relevant keywords. Papers from identified articles were collected. Two researchers rated the certainty in the estimates using the GRADE approach. Combining 15 effect sizes from 14 studies based on the random-effects analysis, we found that artichoke significantly reduced TG (weighed mean difference [WMD]: -17.01 mg/dl, 95% CI: -23.88, -10.13, p = .011), TC (WMD: -17.01 mg/dl, 95% CI: -23.88, -10.13, p < .001), and LDL-C (WMD: -17.48 mg/dl, 95%CI: -25.44, -9.53, p < .001). No significant effect of artichoke on HDL-C level was detected (WMD: 0.78 mg/dl, 95%CI: -0.93, 2.49, p = .371). Combining the two effect sizes revealed that artichoke juice supplementation significantly reduced TG (WMD: -3.34 mg/dl, 95%CI: -5.51, -1.17, p = .003), TC (WMD: -18.04 mg/dl, 95%CI: -20.30, -15.78, p < .001), LDL-C (WMD: -1.75 mg/dl, 95%CI: -3.02, -0.48, p = .007), and HDL-C levels (WMD: -4.21 mg/dl, 95%CI: -5.49, -2.93, p < .001). In conclusion, we found that artichoke supplementation may favor CVD prevention by acting in improving the lipid profile. © 2021 John Wiley & Sons Ltd. DOI: 10.1002/ptr.7247 PMID: 34569671 [Indexed for MEDLINE]
9. Phytother Res. 2021 Nov;35(11):6324-6334. doi: 10.1002/ptr.7279. Epub 2021 Sep 17. The effects of co-administration of artichoke leaf extract supplementation with metformin and vitamin E in patients with nonalcoholic fatty liver disease: A randomized clinical trial. Majnooni MB(1), Ataee M(2), Bahrami G(3), Heydarpour F(4), Aneva IY(5), Farzaei MH(3), Ahmadi-Juoibari T(2). Author information: (1)Student Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran. (2)Clinical Research Development Center, Imam Khomeini and Dr Mohammad Kermanshahi and Farabi Hospitals, Kermanshah University of Medical Sciences, Kermanshah, Iran. (3)Pharmaceutical Sciences Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran. (4)Social Development and Health Promotion Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran. (5)Institute of Biodiversity and Ecosystem Research, Bulgarian Academy of Sciences, Sofia, Bulgaria. Medicinal plants are widely used as a complementary therapy to treat complex diseases, such as nonalcoholic fatty liver disease (NAFLD). Therefore, this study was done to investigate the effect of co-administration of artichoke leaf extract supplement (ALES) with conventional medicines on patients with NAFLD. The clinical trial was based on patients randomly divided into three groups involving metformin-vitamin E (ME), metformin-ALES (MA), and vitamin E-ALES (EA). The effectiveness of treatment in the treated groups was evaluated using liver ultrasonography and biochemical markers. After 12 weeks of treatment, the results showed that the rate of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) was significantly reduced within all the study groups (p < .05). Liver ultrasonographic findings revealed that the rate of fat accumulation in liver of patients was decreased significantly within all the study groups and it was increased in the subjects with grade 0 fatty liver (without fat accumulation) in the MA and EA groups by 23.3 and 17.2%, respectively. In summary, the results of the present study showed that the concomitant use of ALES with metformin and vitamin E can have beneficial effects on amelioration of complications in patients with NAFLD. However, larger-scale clinical trial studies are required in this regard. © 2021 John Wiley & Sons Ltd. DOI: 10.1002/ptr.7279 PMID: 34533249 [Indexed for MEDLINE]
10. Am J Physiol Endocrinol Metab. 2021 Jun 1;320(6):E1119-E1137. doi: 10.1152/ajpendo.00629.2020. Epub 2021 May 3. Effects of Totum-63 on glucose homeostasis and postprandial glycemia: a translational study. Chavanelle V(1), Otero YF(1), Le Joubioux F(2), Ripoche D(1), Bargetto M(2), Vluggens A(1), Montaurier C(3), Pickering G(4)(5), Ducheix G(4)(5), Dubray C(4)(5), Dualé C(4)(5), Boulliau S(4)(5), Macian N(4)(5), Marceau G(6), Sapin V(6), Dutheil F(7), Guigas B(8), Maugard T(9), Boisseau N(10), Cazaubiel M(2), Peltier SL(2), Sirvent P(1). Author information: (1)Valbiotis R&D Riom Center, Riom, France. (2)Valbiotis R&D Perigny Center, Périgny, France. (3)Human Nutrition Unit, INRA Research Center, Clermont-Ferrand, France. (4)CHU Clermont-Ferrand, Centre d'Investigation Clinique, Clermont-Ferrand, France. (5)INSERM, Clermont-Ferrand, France. (6)Biochemistry and Molecular Genetics Department, University Hospital, Clermont-Ferrand, France. (7)Université Clermont Auvergne, CNRS, LaPSCo, Physiological and Psychosocial Stress, CHU Clermont-Ferrand, University Hospital of Clermont-Ferrand, Preventive and Occupational Medicine, Clermont-Ferrand, France. (8)Department of Parasitology, Leiden University Medical Center, Leiden, The Netherlands. (9)La Rochelle Université - LIENSs UMR CNRS 7266, La Rochelle, France. (10)Université Clermont Auvergne, Clermont-Ferrand, France. Global prevalence of type 2 diabetes (T2D) is rising and may affect 700 million people by 2045. Totum-63 is a polyphenol-rich natural composition developed to reduce the risk of T2D. We first investigated the effects of Totum-63 supplementation in high-fat diet (HFD)-fed mice for up to 16 wk and thereafter assessed its safety and efficacy (2.5 g or 5 g per day) in 14 overweight men [mean age 51.5 yr, body mass index (BMI) 27.6 kg·m-2] for 4 wk. In HFD-fed mice, Totum-63 reduced body weight and fat mass gain, whereas lean mass was unchanged. Moreover, fecal energy excretion was higher in Totum-63-supplemented mice, suggesting a reduction of calorie absorption in the digestive tract. In the gut, metagenomic analyses of fecal microbiota revealed a partial restoration of HFD-induced microbial imbalance, as shown by principal coordinate analysis of microbiota composition. HFD-induced increase in HOMA-IR score was delayed in supplemented mice, and insulin response to an oral glucose tolerance test was significantly reduced, suggesting that Totum-63 may prevent HFD-related impairments in glucose homeostasis. Interestingly, these improvements could be linked to restored insulin signaling in subcutaneous adipose tissue and soleus muscle. In the liver, HFD-induced steatosis was reduced by 40% (as shown by triglyceride content). In the subsequent study in men, Totum-63 (5 g·day-1) improved glucose and insulin responses to a high-carbohydrate breakfast test (84% kcal carbohydrates). It was well tolerated, with no clinically significant adverse events reported. Collectively, these data suggest that Totum-63 could improve glucose homeostasis in both HFD-fed mice and overweight individuals, presumably through a multitargeted action on different metabolic organs.NEW & NOTEWORTHY Totum-63 is a novel polyphenol-rich natural composition developed to reduce the risk of T2D. Totum-63 showed beneficial effects on glucose homeostasis in HFD-fed mice, presumably through a multitargeted action on different metabolic organs. Totum-63 was well tolerated in humans and improved postprandial glucose and insulin responses to a high-carbohydrate breakfast test. DOI: 10.1152/ajpendo.00629.2020 PMCID: PMC8285600 PMID: 33938234 [Indexed for MEDLINE] Conflict of interest statement: One or more authors are employed by Valbiotis. Valbiotis has designed and patented Totum-63. None of the other authors has any conflicts of interest, financial or otherwise, to disclose.
11. Nutrients. 2019 Aug 5;11(8):1805. doi: 10.3390/nu11081805. Impact of Foods and Dietary Supplements Containing Hydroxycinnamic Acids on Cardiometabolic Biomarkers: A Systematic Review to Explore Inter-Individual Variability. Martini D(1), Chiavaroli L(2)(3), González-Sarrías A(4), Bresciani L(1), Palma-Duran SA(5), Dall'Asta M(2), Deligiannidou GE(6), Massaro M(7), Scoditti E(7), Combet E(5), Maksimova V(8), Urpi-Sarda M(9)(10), Kontogiorgis CA(6), Andrés-Lacueva C(9)(10), Gibney ER(11), Del Rio D(1)(12), Morand C(13), Garcia-Aloy M(9)(10), Rodriguez-Mateos A(14), Mena P(15). Author information: (1)Human Nutrition Unit, Department of Veterinary Science, University of Parma, 43121 Parma, Italy. (2)Human Nutrition Unit, Department of Food & Drug, University of Parma, 43124 Parma, Italy. (3)Department of Nutritional Sciences, Faculty of Medicine, University of Toronto, Toronto, ON M5S 1A8, Canada. (4)Laboratory of Food and Health, Research Group on Quality, Safety and Bioactivity of Plant Foods, CEBAS-CSIC, 30100 Murcia, Spain. (5)School of Medicine, Dentistry and Nursing, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow G31 2ER, UK. (6)Laboratory of Hygiene and Environmental Protection, Department of Medicine, Democritus University of Thrace, 68100 Alexandroupolis, Greece. (7)National Research Council (CNR), Institute of Clinical Physiology (IFC), 73100 Lecce, Italy. (8)Department of Applied Pharmacy, Faculty of Medical Sciences, Goce Delcev University, 2000 Stip, Macedonia. (9)Biomarkers & Nutrimetabolomic Laboratory, Department of Nutrition, Food Sciences and Gastronomy, XaRTA, INSA, Faculty of Pharmacy and Food Sciences, University of Barcelona, 08921 Santa Coloma de Gramenet, Spain. (10)CIBER de Fragilidad y Envejecimiento Saludable (CIBERFES), Instituto de Salud Carlos III, 08028 Barcelona, Spain. (11)UCD Institute of Food and Health, University College Dublin, Dublin 4, Ireland. (12)School of Advanced Studies on Food and Nutrition, University of Parma, Parma, Italy and Microbiome Research Hub, University of Parma, 43124 Parma, Italy. (13)Université Clermont Auvergne, Institut National de la Recherche Agronomique (INRA), Unité de Nutrition Humaine (UNH), CRNH Auvergne, F-63000 Clermont-Ferrand, France. (14)Department of Nutritional Sciences, School of Life Course Sciences, Faculty of Life Science and Medicine, King's College London, London SE1 9NH, UK. (15)Human Nutrition Unit, Department of Food & Drug, University of Parma, 43124 Parma, Italy. pedromiguel.menaparreno@unipr.it. Plant-based diets rich in bioactive compounds such as polyphenols have been shown to positively modulate the risk of cardiometabolic (CM) diseases. The inter-individual variability in the response to these bioactives may affect the findings. This systematic review aimed to summarize findings from existing randomized clinical trials (RCTs) evaluating the effect of hydroxycinnamic acids (HCAs) on markers of CM health in humans. Literature searches were performed in PubMed and the Web of Science. RCTs on acute and chronic supplementation of HCA-rich foods/extracts on CM biomarkers were included. Forty-four RCTs (21 acute and 23 chronic) met inclusion criteria. Comparisons were made between RCTs, including assessments based on population health status. Of the 44 RCTs, only seven performed analyses on a factor exploring inter-individual response to HCA consumption. Results demonstrated that health status is a potentially important effect modifier as RCTs with higher baseline cholesterol, blood pressure and glycaemia demonstrated greater overall effectiveness, which was also found in studies where specific subgroup analyses were performed. Thus, the effect of HCAs on CM risk factors may be greater in individuals at higher CM risk, although future studies in these populations are needed, including those on other potential determinants of inter-individual variability. PROSPERO, registration number CRD42016050790. DOI: 10.3390/nu11081805 PMCID: PMC6723370 PMID: 31387247 [Indexed for MEDLINE] Conflict of interest statement: The authors declare no conflict of interest.
12. Phytother Res. 2019 Aug;33(8):2094-2101. doi: 10.1002/ptr.6402. Epub 2019 Jun 21. Three-arm, placebo-controlled, randomized clinical trial evaluating the metabolic effect of a combined nutraceutical containing a bergamot standardized flavonoid extract in dyslipidemic overweight subjects. Cicero AFG(1), Fogacci F(1), Bove M(1), Giovannini M(1), Borghi C(1). Author information: (1)Department of Medical and Surgical Sciences, Alma Mater Studiorum - Università di Bologna, Bologna, Italy. Our double-blind, placebo-controlled, parallel-group, dose-escalation, clinical trial aimed to test the effect of a combined nutraceutical containing bergamot extract (120-mg flavonoids), phytosterols, vitamin C, and chlorogenic acid from dry artichoke extract on 90 overweight dyslipidemic subjects. Participants were randomly allocated to treatment with two pills of either active treatment or placebo, or a combination of both (a pill per treatment). After 8 weeks, all active-treated groups experienced a significant improvement in triglycerides (TG) versus placebo and in low-density lipoprotein cholesterol (LDL-C) versus baseline and placebo treatments. In the high-dose-treated group, also total cholesterol (TC), nonhigh-density lipoprotein cholesterol (non-HDL-C), γ-glutamil transpeptidasi, high-sensitivity C-reactive protein (hs-CRP), and tumor necrosis factor-α (TNF-α) significantly decreased. At 24-week follow-up, TG levels maintained lower than baseline in all groups. All patients allocated to either low-dose or high-dose active treatment experienced a significant decrease in TG, LDL-C, and homeostatin model assessment of insulin resistance. In subjects taking high-dose active treatment, adiponectin significantly increased, whereas TC, non-HDL-C, insulin (fasting plasma insulin), leptin, leptin/adiponectin ratio, hs-CRP, and TNF-α were significantly reduced. The tested nutraceutical showed to improve lipid and glucose metabolism, adipokines pattern, and systemic inflammation in dyslipidemic overweight subjects. © 2019 John Wiley & Sons, Ltd. DOI: 10.1002/ptr.6402 PMID: 31225673 [Indexed for MEDLINE]
13. Am J Cardiol. 2019 Feb 15;123(4):588-591. doi: 10.1016/j.amjcard.2018.11.018. Epub 2018 Nov 23. Short-Term Effects of Dry Extracts of Artichokeand Berberis in Hypercholesterolemic Patients Without Cardiovascular Disease. Cicero AFG(1), Fogacci F(2), Bove M(2), Giovannini M(2), Veronesi M(2), Borghi C(2). Author information: (1)Department of Medical and Surgical Sciences, Alma Mater Studiorum - Università di Bologna, Bologna, Italy. Electronic address: arrigo.cicero@unibo.it. (2)Department of Medical and Surgical Sciences, Alma Mater Studiorum - Università di Bologna, Bologna, Italy. Hypercholesterolemia represents one of the main reversible cardiovascular risk factors. In this pilot clinical trial, we have tested the short-term efficacy and safety of a new combined cholesterol-lowering nutraceutical containing artichoke dry extract and berberine at enhanced bioavailability in subjects with moderate polygenic hypercholesterolemia in primary prevention for cardiovascular disease. After 2 months of treatment, the tested nutraceutical induced a significant reduction in plasma total cholesterol (-19%), low-density lipoprotein cholesterol (-16%), non-high-density lipoprotein cholesterol (-19%) and triglyceride levels (-15%), in association with a standardized control diet. No side effect has been observed during the trial. In conclusion, on the short-term, the tested nutraceutical has been shown to be well tolerated and effective, even if not containing any statin-like compound. Copyright © 2018. Published by Elsevier Inc. DOI: 10.1016/j.amjcard.2018.11.018 PMID: 30528419 [Indexed for MEDLINE]
14. J Integr Med. 2018 Sep;16(5):329-334. doi: 10.1016/j.joim.2018.05.006. Epub 2018 Jun 1. TCF7L2-rs7903146 polymorphism modulates the effect of artichoke leaf extract supplementation on insulin resistance in metabolic syndrome: a randomized, double-blind, placebo-controlled trial. Ebrahimi-Mameghani M(1), Asghari-Jafarabadi M(2), Rezazadeh K(3). Author information: (1)Nutrition Research Center, School of Nutrition & Food Sciences, Tabriz University of Medical Sciences, Tabriz 5166614711, Iran. (2)Road Traffic Injury Research Center, Tabriz University of Medical Sciences, Tabriz 5166614711, Iran; Department of Statistics and Epidemiology, School of Health, Tabriz University of Medical Sciences, Tabriz 5166614711, Iran. (3)Nutrition Research Center, School of Nutrition & Food Sciences, Tabriz University of Medical Sciences, Tabriz 5166614711, Iran; Student Research Committee, School of Nutrition & Food Sciences, Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address: rezazadekhatere@gmail.com. BACKGROUND: Transcription factor 7-like 2 (TCF7L2)-rs7903146 polymorphism is associated with increased risk of type 2 diabetes. The response of insulin and insulin resistance to artichoke leaf extract (ALE) may be affected by TCF7L2-rs7903146 polymorphism. OBJECTIVE: This study examined the effects of ALE supplementation on metabolic parameters of the TCF7L2-rs7903146 polymorphism in patients with metabolic syndrome (MetS). DESIGN, SETTING, PARTICIPANTS AND INTERVENTIONS: This double-blind clinical trial was conducted on 80 patients with MetS in Sina Clinic, Khoy, Iran. The patients were randomized into ALE or placebo groups to receive either ALE (1800 mg/d as four tablets) or matching placebo for 12 weeks. MAIN OUTCOME MEASURES: Anthropometric indices, blood pressure, glucose and lipid profile levels were measured before and after the study. Moreover, patients were genotyped for TCF7L2 polymorphism. RESULTS: ALE supplementation decreased insulin level and the homeostasis model assessment of insulin resistance (HOMA-IR) in patients with the TT genotype of TCF7L2-rs7903146 polymorphism (P < 0.05). There was no significant interaction between blood pressure, glucose and lipid profile response to ALE supplementation. CONCLUSION: The responses of insulin and HOMA-IR to ALE supplementation have shown an interaction with single-nucleotide polymorphism rs7903146 in TCF7L2. TRIAL REGISTRATION: Iranian Registry of Clinical Trial IRCT201409033320N9. Copyright © 2018 Shanghai Changhai Hospital. Published by Elsevier B.V. All rights reserved. DOI: 10.1016/j.joim.2018.05.006 PMID: 30177026 [Indexed for MEDLINE]
⚠️ 면책 고지
이 정보는 일반 교육 목적이며 의료 진단/처방을 대체하지 않습니다.